We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effectiveness Study of Single Photon Emission Computed Tomography (SPECT) Versus Positron Emission Tomography (PET) Myocardial Perfusion Imaging

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00976053
First Posted: September 14, 2009
Last Update Posted: October 31, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Blue Cross Blue Shield
Cardiovascular Imaging Technologies
Saint Luke's Cardiovascular Consultants
Mid America Heart Institute
Information provided by (Responsible Party):
Timothy M. Bateman, Aspire Foundation
  Purpose
The purpose of this study is to compare pharmacologic stress myocardial perfusion PET with pharmacologic stress myocardial perfusion SPECT in a near-simultaneous, head-to-head comparison in the same patient. The investigators hypothesize that pharmacologic stress myocardial perfusion PET will prove superior to pharmacologic stress myocardial perfusion SPECT as a first-line diagnostic test for higher-risk patients with known coronary artery disease (CAD) who present with symptoms consistent with possible worsening of their CAD.

Condition Intervention Phase
Coronary Artery Disease Procedure: Myocardial perfusion imaging Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Clinical Effectiveness of Pharmacologic Stress Radionuclide Myocardial Perfusion Imaging as a Guide to Management of Patients With Known CAD: Comparison of Single-Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET)

Resource links provided by NLM:


Further study details as provided by Timothy M. Bateman, Aspire Foundation:

Primary Outcome Measures:
  • Diagnostic failure of SPECT vs PET [ Time Frame: 60 days ]

Secondary Outcome Measures:
  • Composite of diagnostic or clinical failure [ Time Frame: 12 months ]
  • Each of individual components of clinical failure [ Time Frame: 12 months ]
  • Relative effect on quality of life [ Time Frame: 3 months, 6 months ]
  • Relative direct and downstream costs [ Time Frame: 3 months, 6 months, 12 months ]

Enrollment: 330
Study Start Date: June 2009
Study Completion Date: October 2014
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: SPECT myocardial perfusion imaging Procedure: Myocardial perfusion imaging
Randomization assignment to one of SPECT or PET myocardial perfusion imaging
Active Comparator: PET myocardial perfusion imaging Procedure: Myocardial perfusion imaging
Randomization assignment to one of SPECT or PET myocardial perfusion imaging

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of coronary artery disease
  • New or worsening symptoms
  • Out-patients and in-hospital patients

Exclusion Criteria:

  • Creatinine above 2.5 mg%
  • PCI within prior 6 months
  • Pregnant females
  • Cardiomyopathy (LVEF below 40%)
  • Significant valvular heart disease
  • Body mass index greater than 38
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00976053


Locations
United States, Missouri
Saint Luke's Cardiovascular Consultants
Kansas City, Missouri, United States, 64111
Sponsors and Collaborators
Aspire Foundation
Blue Cross Blue Shield
Cardiovascular Imaging Technologies
Saint Luke's Cardiovascular Consultants
Mid America Heart Institute
Investigators
Principal Investigator: Timothy M Bateman, M.D. Aspire Foundation
  More Information

Responsible Party: Timothy M. Bateman, Prinicpal Investigator/Medical Director, Aspire Foundation
ClinicalTrials.gov Identifier: NCT00976053     History of Changes
Other Study ID Numbers: 09-307
First Submitted: September 11, 2009
First Posted: September 14, 2009
Last Update Posted: October 31, 2014
Last Verified: October 2014

Keywords provided by Timothy M. Bateman, Aspire Foundation:
Myocardial perfusion imaging
Single photon emission computed tomography
Positron emission tomography

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases